Press Releases Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Delayed OTC Markets Other stock markets 11:05:41 2024-05-17 am EDT			5-day change	1st Jan Change
0.43 ^USD	-10.42%		+13.22%	-97.65%

12:25pm	North American Morning Briefing : The "Everything -2-	DJ
May. 15	Transcript : Panbela Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Panbela Provides Business Update and Reports Q1 2024 Financial Results	May. 15	AQ
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac	May. 06	GL
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024	May. 01	GL
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week	Apr. 30	GL
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025	Apr. 22	GL
Panbela Announces Poster Presentation at American Association for Cancer Research	Apr. 18	AQ
Panbela Announces Poster Presentation at American Association for Cancer Research	Apr. 18	GL
Panbela Announces Transfer to OTCQB Market	Apr. 16	GL
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results	Mar. 26	AQ
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024	Mar. 12	GL
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements	Feb. 15	GL
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements	Feb. 15	AQ
Panbela Announces Closing of Approximately $9.0 Million Public Offering	Feb. 01	GL
Panbela Announces Closing of Approximately $9.0 Million Public Offering	Feb. 01	AQ
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)	Jan. 30	GL
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)	Jan. 30	AQ
Panbela Announces Pricing of Approximately $9.0 Million Public Offering	Jan. 29	AQ
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum	Jan. 25	AQ
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial	Jan. 18	AQ
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024	Jan. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Press Releases

Filters